Inclusion Criteria:

- Subjects who provide written informed consent

- Age over 18 years

- Histologically proven unresectable gastric cancer

- ECOG performance status of 0-2

- At least one uni-dimensionally measurable lesion by RECIST criteria ver 1.1

- Adequate organ system function absolute neutrophil count > 1,500/µL, platelets >
100,000/µL, hemoglobin > 9g/dl Total bilirubin < 1.5 times upper limit of normal
(ULN), AST and ALT < 2.5 times ULN, PT (INR), PTT < 1.2 times UNL Serum creatinine
less than 1.5 mg/dL or Calculated Ccr at least 50 mL/min, Urine Protein to Creatinine
Ratio (UPC) less than 1

- female with Non-childbearing potential

Exclusion Criteria:

- Prior malignancy

- History or clinical evidence of central nervous system (CNS) metastases or
leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS
metastases, are asymptomatic, and have had no requirement for steroids or
anti-seizure medication for 6 months prior to first dose of study drug

- Clinically significant gastrointestinal abnormalities that may increase the risk for
gastrointestinal bleeding including

- Clinically significant gastrointestinal abnormalities that may affect absorption of
investigational product

- Presence of uncontrolled infection

- Corrected QT interval (QTc) above 480 msecs using Bazett's formula

- History of any one or more of the following cardiovascular conditions within the past
6 months: Cardiac angioplasty or stenting, Myocardial infarction, Unstable angina,
Coronary artery bypass graft surgery, Symptomatic peripheral vascular disease, Class
II or higher congestive heart failure

- Poorly controlled hypertension while on antihypertensive agents

- History of cerebrovascular accident including transient ischemic attack (TIA),
pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months

- Prior major surgery or trauma within 28 days prior to first dose of study drug and/or
presence of any non-healing wound, fracture, or ulcer

- Evidence of active bleeding or bleeding diathesis

- Hemoptysis within 6 weeks of first dose of study drug

- Any serious and/or unstable preexisting medical, psychiatric, or other condition that
could interfere with subject's safety, provision of informed consent, or compliance
to study procedures

- Unable or unwilling to discontinue use of prohibited medications listed in the
protocol

- Treatment with any of the following anti-cancer therapies;Radiation therapy, surgery
or tumor embolization within 14 days prior to the first dose of pazopanib; biologic
therapy, immunotherapy, investigational therapy or hormonal therapy within 14 days or
five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib;
No prior chemotherapy except adjuvant chemotherapy (Patients who received adjuvant
chemotherapy at least 6 months prior to study entry will be allowed regardless of
chemotherapeutic regimen

- Pre-existing grade 2 (or higher) motor or sensory neuropathy by CTCAE v4.0

- Known allergy to study drugs